Dose‐dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin‐like growth factor‐1
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The prevalence of obesity, an established risk and progression factor for breast and many other cancer types, remains very high in the United States and throughout the world. Calorie restriction (CR), a reduced‐calorie dietary regimen typically involving a 20–40% reduction in calorie consumption, prevents or reverses obesity, and inhibits mammary and other types of cancer in multiple tumor model systems. Unfortunately, the mechanisms underlying the tumor inhibitory effects of CR are poorly understood, and a better understanding of these mechanisms may lead to new intervention targets and strategies for preventing or controlling cancer. We have previously shown that the anticancer effects of CR are associated with decreased systemic levels of insulin‐like growth factor‐1 (IGF‐1), the primary source of which is liver. We have also reported that CR strongly suppresses tumor development and growth in multiple mammary cancer models. To identify CR‐responsive genes and pathways, and to further characterize the role of IGF‐1 as a mediator of the anticancer effects of CR, we assessed hepatic and mammary gland gene expression, hormone levels and growth of orthotopically transplanted mammary tumors in control and CR mice with and without exogenous IGF‐1. C57BL/6 mice were fed either control AIN‐76A diet ad libitum (AL), subjected to 20%, 30%, or 40% CR plus placebo timed‐release pellets, or subjected to 30% or 40% CR plus timed‐release pellets delivering murine IGF‐1 (mIGF‐1, 20 μ g/day). Compared with AL‐fed controls, body weights were decreased 14.3% in the 20% CR group, 18.5% in the 30% CR group, and 38% in the 40% CR group; IGF‐1 infusion had no effect on body weight. Hepatic transcriptome analyses indicated that compared with 20% CR, 30% CR significantly modulated more than twice the number of genes and 40% CR more than seven times the number of genes. Many of the genes specific to the 40% CR regimen were hepatic stress‐related and/or DNA damage‐related genes. Exogenous IGF‐1 rescued the hepatic expression of several metabolic genes and pathways affected by CR. Exogenous IGF‐1 also rescued the expression of several metabolism‐ and cancer‐related genes affected by CR in the mammary gland. Furthermore, exogenous IGF‐1 partially reversed the mammary tumor inhibitory effects of 30% CR. We conclude that several genes and pathways, particularly those associated with macronutrient and steroid hormone metabolism, are associated with the anticancer effects of CR, and that reduced IGF‐1 levels can account, at least in part, for many of the effects of CR on gene expression and mammary tumor burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“We and others have shown that treatment with the mTOR inhibitor rapamycin partially mimics the effects of CR [10, 14, 15].”
BackgroundOverweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“Obesity increases the risk of developing and/or dying from a host of diseases, including breast cancer in postmenopausal women [4].”
BackgroundCritical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 1×
“IGF-1 exerts its effects on cellular growth and metabolism, at least in part, through activation of the phosphatidylinositol 3-kinase (PI3K)/ Akt/mammalian target of rapamycin (mTOR) pathway [12, 13].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“IGF-1 exerts its effects on cellular growth and metabolism, at least in part, through activation of the phosphatidylinositol 3-kinase (PI3K)/ Akt/mammalian target of rapamycin (mTOR) pathway [12, 13].”
BackgroundPPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460 · cited 1×
“Leptin has been shown to positively influence breast cancer cell proliferation, invasion, and metastasis in vitro and in vivo [28].”
BackgroundGene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427 · cited 1×
“To our knowledge, this is the first report that CR modulates Fabp5, although its expression has been shown to be increased in human nonalcoholic fatty liver disease [33, 34].”
Background
Cited by
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Cawthorn, W. P., Scheller, E. L., Learman, B. S., Parlee, S. D., Simon, B. R., Mori, H., Ning, X., Bree, A. J., Schell, B., Broome, D. T., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.06.003 · Cited by 531
Obesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262
“The link has also been supported by animal experiments inwhich obesity and cancer have been modified by dietary means (Nogueira et al., 2012a, 2012b).”
BackgroundA framework for examining how diet impacts tumour metabolism
Lien, E. C., & Vander Heiden, M. G. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0198-5 · Cited by 139
Patel, S. A., Chaudhari, A., Gupta, R., Velingkaar, N., & Kondratov, R. V. (2016) · The FASEB Journal · doi:10.1096/fj.15-282475 · Cited by 94
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
Metadata
- Authors
- Nogueira, L. M., Lavigne, J. A., Chandramouli, G. V. R., Lui, H., Barrett, J. C., & Hursting, S. D.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2012-08-06
- Volume
- 1
- Issue
- 2
- Pages
- 275-288
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W1995843773
- Cited by
- 56
- References
- 7
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.